MedTech Acquisition (MedTech Acquisition) Sloan Ratio % : -1,958.88% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

MedTech Acquisition's Sloan Ratio for the quarter that ended in Jun. 2023 was -1,958.88%.

Warning Sign:

When sloan ratio (-1114.14)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Jun. 2023, MedTech Acquisition has a Sloan Ratio of -1,958.88%, indicating earnings are more likely to be made up of accruals.

MedTech Acquisition Sloan Ratio % Historical Data

The historical data trend for MedTech Acquisition's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition Sloan Ratio % Chart

MedTech Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Sloan Ratio %

2.57

-1,114.14

MedTech Acquisition Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Sloan Ratio %	Get a 7-Day Free Trial							-	-	-1,114.13	-1,109.60	-1,958.88

Competitive Comparison of MedTech Acquisition's Sloan Ratio %

For the Shell Companies subindustry, MedTech Acquisition's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedTech Acquisition's Sloan Ratio % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's Sloan Ratio % falls into.

MedTech Acquisition Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

MedTech Acquisition's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2022 )	-	Cash Flow from Operations (A: Dec. 2022 )
	-	Cash Flow from Investing (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2022 )
	=	(5.539	-	-2.737
	-	233.198)	/	20.188
	=	-1,114.14%

MedTech Acquisition's Sloan Ratio for the quarter that ended in Jun. 2023 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Jun. 2023 )
	=	(-1.127	-	-2.627
	-	241.228)	/	12.238
	=	-1,958.88%

MedTech Acquisition's Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was 0.659 (Sep. 2022 ) + -0.343 (Dec. 2022 ) + -0.448 (Mar. 2023 ) + -0.995 (Jun. 2023 ) = $-1.13 Mil.
MedTech Acquisition's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was -0.349 (Sep. 2022 ) + -1.266 (Dec. 2022 ) + -0.698 (Mar. 2023 ) + -0.314 (Jun. 2023 ) = $-2.63 Mil.
MedTech Acquisition's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 was 0.287 (Sep. 2022 ) + 232.82 (Dec. 2022 ) + -0.234 (Mar. 2023 ) + 8.355 (Jun. 2023 ) = $241.23 Mil.

MedTech Acquisition (NAS:MTACU) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2023, MedTech Acquisition has a Sloan Ratio of -1,958.88%, indicating earnings are more likely to be made up of accruals.

MedTech Acquisition Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

MedTech Acquisition (MedTech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

48 Maple Avenue, Greenwich, CT, USA, 06830

Website

MedTech Acquisition Corp is a blank check company.

Executives

Magnetar Financial Llc	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc	10 percent owner	1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman	10 percent owner	C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell	director	222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin	director, 10 percent owner, officer: Chief Financial Officer
Karim Karti	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey	director, 10 percent owner, officer: Chief Executive Officer	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss	officer: Chief Admin Officer and Sec.	585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022